World's Best Scientists 2026 revealed!
Priti Hegde

Priti Hegde

D-Index & Metrics

Biology and Biochemistry

D-Index
53
Citations
35923
World Ranking
15872
National Ranking
6591

Overview

Priti Hegde is affiliated with Genentech in the United States and has a research focus primarily in the fields of Medicine and Biochemistry, Genetics and Molecular Biology. Their work spans diverse subfields including Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Immunology, and Molecular Biology.

The main topics addressed in their research include:

  • Cancer Genomics and Diagnostics
  • Cancer Immunotherapy and Biomarkers
  • Lung Cancer Treatments and Mutations
  • Colorectal Cancer Treatments and Studies
  • CAR-T cell therapy research
  • Genetic factors in colorectal cancer
  • Bladder and Urothelial Cancer Treatments

Hegde has published extensively, with a notable presence in journals such as the Journal of Clinical Oncology, Cancer Research, PLoS ONE, Nature Communications, and Cancer Cell. The frequency of publications in these venues are:

  • Journal of Clinical Oncology: 6 publications
  • Cancer Research: 5 publications
  • PLoS ONE: 4 publications
  • Nature Communications: 3 publications
  • Cancer Cell: 2 publications

Among the recent papers authored or co-authored by Hegde are:

  • "Top 10 Challenges in Cancer Immunotherapy," 2020, Immunity
  • "Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade," 2020, Cancer Cell
  • "Clinical and analytical validation of FoundationOne Liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin," 2020, PLoS ONE
  • "High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade," 2020, Nature Medicine
  • "Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy," 2020, Science Translational Medicine

The scientist frequently collaborates with the following co-authors:

  • David Fabrizio
  • Sanjeev Mariathasan
  • Brian M. Alexander
  • Garrett M. Frampton
  • Thomas Powles

Best Publications

  • Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

    Roy S. Herbst;Jean Charles Soria;Marcin Kowanetz;Gregg D. Fine

  • TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells.

    Sanjeev Mariathasan;Shannon J. Turley;Dorothee Nickles;Alessandra Castiglioni

  • MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

    Thomas Powles;Joseph Paul Eder;Gregg D. Fine;Fadi S. Braiteh

  • Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial.

    Thomas Powles;Ignacio Durán;Michiel S van der Heijden;Yohann Loriot

  • Top 10 Challenges in Cancer Immunotherapy

    Priti S. Hegde;Daniel S. Chen

  • A Concise Guide to cDNA Microarray Analysis

    P. Hegde;R. Qi;K. Abernathy

  • Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma

    David F. McDermott;Mahrukh A. Huseni;Michael B. Atkins;Robert J. Motzer

  • Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

    David R. Gandara;Sarah M. Paul;Marcin Kowanetz;Erica Schleifman

  • The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition.

    Priti S. Hegde;Vaios Karanikas;Stefan Evers

  • Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma

    Jeffrey J. Wallin;Johanna C. Bendell;Roel Funke;Mario Sznol

  • Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

    David F. McDermott;Jeffrey A. Sosman;Mario Sznol;Christophe Massard

  • Activation of Peroxisome Proliferator–Activated Receptor (PPAR)δ Promotes Reversal of Multiple Metabolic Abnormalities, Reduces Oxidative Stress, and Increases Fatty Acid Oxidation in Moderately Obese Men

    Ulf Risérus;Dennis Sprecher;Tony Johnson;Eric Olson

  • A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

    Wenle Xia;Sarah Bacus;Priti Hegde;Intisar Husain

  • High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.

    Kobe C. Yuen;Li-Fen Liu;Vinita Gupta;Shravan Madireddi

  • Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics

    Priti S. Hegde;Jeffrey J. Wallin;Christoph Mancao

  • Molecular Subsets in Renal Cancer Determine Outcome to Checkpoint and Angiogenesis Blockade

    Robert J. Motzer;Romain Banchereau;Habib Hamidi;Thomas Powles

  • Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy.

    Maud Mayoux;Andreas Roller;Vesna Pulko;Stefano Sammicheli

  • Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

    Thomas Sandmann;Richard Bourgon;Josep Garcia;Congfen Li

  • Interplay of transcriptomics and proteomics

    Priti S Hegde;Ian R White;Christine Debouck

  • NF-κB Mediates the Stimulation of Cytokine and Chemokine Expression by Human Articular Chondrocytes in Response to Fibronectin Fragments

    Judit I. Pulai;Hong Chen;Hee Jeong Im;Sanjay Kumar

Frequent Co-Authors

Thomas Powles
Thomas Powles Queen Mary University of London
Nicholas J. Vogelzang
Nicholas J. Vogelzang University of Nevada Reno
David F. McDermott
David F. McDermott Beth Israel Deaconess Medical Center
David R. Gandara
David R. Gandara University of California, Davis
Joaquim Bellmunt
Joaquim Bellmunt Beth Israel Deaconess Medical Center
Scott N. Gettinger
Scott N. Gettinger Yale University
Ira Mellman
Ira Mellman Parker Institute for Cancer Immunotherapy
Naiyer A. Rizvi
Naiyer A. Rizvi Columbia University Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring Biology and Biochemistry opens doors to a wide range of online degree options and career routes in the health sciences. For example, if you are interested in nutrition and wellness, you can consider a holistic nutrition degree that emphasizes a whole-body approach to health.

Broader career opportunities in healthcare leadership can be accessed through online healthcare MBA programs, where you’ll develop the business and management skills essential for the fast-changing medical field.

Those with an eye for detail may be interested in medical data, where becoming a certified professional coder is a popular certification. Understanding the medical coding jobs salary landscape can help guide your next steps, as this field is in high demand and offers strong earning potential.

Ultimately, whether your interest lies in research, clinical practice, healthcare management, or coding, exploring these online options broadens your professional outlook and helps you find the right career path.

Best Scientists Citing Priti Hegde

Trending Scientists

Recently Published Articles